Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 16;23(6):3214.
doi: 10.3390/ijms23063214.

Collagen Family and Other Matrix Remodeling Proteins Identified by Bioinformatics Analysis as Hub Genes Involved in Gastric Cancer Progression and Prognosis

Affiliations

Collagen Family and Other Matrix Remodeling Proteins Identified by Bioinformatics Analysis as Hub Genes Involved in Gastric Cancer Progression and Prognosis

Mihaela Chivu-Economescu et al. Int J Mol Sci. .

Abstract

Gastric cancer has remained in the top five cancers for over ten years, both in terms of incidence and mortality due to the shortage of biomarkers for disease follow-up and effective therapies. Aiming to fill this gap, we performed a bioinformatics assessment on our data and two additional GEO microarray profiles, followed by a deep analysis of the 40 differentially expressed genes identified. PPI network analysis and MCODE plug-in pointed out nine upregulated hub genes coding for proteins from the collagen family (COL12A1, COL5A2, and COL10A1) or involved in the assembly (BGN) or degradation of collagens (CTHRC1), and also associated with cell adhesion (THBS2 and SPP1) and extracellular matrix degradation (FAP, SULF1). Those genes were highly upregulated at the mRNA and protein level, the increase being correlated with pathological T stages. The high expression of BGN (p = 8 × 10-12), THBS2 (p = 1.2 × 10-6), CTHRC1 (p = 1.1 × 10-4), SULF1 (p = 3.8 × 10-4), COL5A1 (p = 1.3 × 10-4), COL10A1 (p = 5.7 × 10-4), COL12A1 (p = 2 × 10-3) correlated with poor overall survival and an immune infiltrate based especially on immunosuppressive M2 macrophages (p-value range 4.82 × 10-7-1.63 × 10-13). Our results emphasize that these genes could be candidate biomarkers for GC progression and prognosis and new therapeutic targets.

Keywords: biomarkers; cell adhesion; collagens; extracellular matrix; survival; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Venn diagrams of upregulated and downregulated genes in all three GC microarray datasets.
Figure 2
Figure 2
DAVID gene ontology enrichment analysis for common DEGs performed for biological process, cellular component, molecular function, significant keywords, and KEEG pathway.
Figure 3
Figure 3
Protein–protein interaction (PPI) analysis. (A) PPI networks of the common upregulated DEGs. (B) Identification of nine hub genes according to MCODE score.
Figure 4
Figure 4
The expression levels of hub genes in GC. (A) The mRNA expression was correlated with pathological T stages. The asterisk represents the comparison between a specific stage and the normal group, or between different stages. * p < 0.05, ** p < 0.01, *** p < 0.001. (B) Representative western blotting for COL10A1, BGN, and FAP proteins in 4 paired gastric tumor (T) and adjacent non-tumor tissues (N) with progressive stages from T1 to T4.
Figure 5
Figure 5
Overall survival curves according to high and low DEG expression. High gene expression has a higher hazard ratio (HR) for poor overall survival.
Figure 6
Figure 6
Analysis of tumor infiltrate in GC. Correlation between hub genes and 12 immune cell types in tumor microenvironment based on Spearman’s rho.

Similar articles

Cited by

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Eusebi L.H., Telese A., Marasco G., Bazzoli F., Zagari R.M. Gastric cancer prevention strategies: A global perspective. J. Gastroenterol. Hepatol. 2020;35:1495–1502. doi: 10.1111/jgh.15037. - DOI - PubMed
    1. Mokadem I., Dijksterhuis W.P.M., van Putten M., Heuthorst L., de Vos-Geelen J.M., Haj Mohammad N., Nieuwenhuijzen G.A.P., van Laarhoven H.W.M., Verhoeven R.H.A. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: A multicenter study. Gastric Cancer. 2019;22:1263–1273. doi: 10.1007/s10120-019-00956-6. - DOI - PMC - PubMed
    1. Li Y., Yang Y., Lu M., Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011;58:2166–2170. doi: 10.5754/hge11753. - DOI - PubMed
    1. Kim K.C., Koh Y.W., Chang H.M., Kim T.H., Yook J.H., Kim B.S., Jang S.J., Park Y.S. Evaluation of HER2 protein expression in gastric carcinomas: Comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann. Surg. Oncol. 2011;18:2833–2840. doi: 10.1245/s10434-011-1695-2. - DOI - PubMed

MeSH terms